Search
SynKIR-110
go.drugbank.com/drugs/DB17365InvestigationalSynKIR-110 are autologous T cells genetically engineered to express an anti-mesothelin killer immunoglobulin-like receptor-chimeric antigen receptor (KIR-CAR).
PRX-ASL
go.drugbank.com/drugs/DB17679ExperimentalPRX-ASL is an intracellular enzyme replacement therapy designed to replace the missing or defective enzyme in patients with argininosuccinate lyase deficiency.
Lepunafusp alfa
go.drugbank.com/drugs/DB19011InvestigationalLepunafusp alfa is under investigation in clinical trial NCT04453085 (An Extension Study of JR-171-101 Study in Patients With MPS I).
Odronextamab
go.drugbank.com/drugs/DB16684ApprovedInvestigational[A254187,A254197] Preliminary studies have shown that in patients with R/R NHL, the use of odronextamab does not lead to the development of neurologic toxicity; however, it can lead to the development
Tefidsogene civaparvovec
go.drugbank.com/drugs/DB16789InvestigationalTefidsogene civaparvovec, formerly known as SB-913, is an investigational therapy for genome editing. … It consists of an adeno-associated virus (AAV) type 2/6 vector and a zinc finger nuclease (ZFN) system that inserts a correct copy of the Iduronate 2-Sulfatase (IDS) gene into the albumin locus in hepatocytes
19-Nor-5-androstenedione
go.drugbank.com/drugs/DB01443ExperimentalIllicit19-Nor-5-andorstenedione is a prohormone which has the potential to affect bodily levels of testosterone once metabolized in vivo. It is regulated in the United States as a schedule III controlled substance, and prohibited by the World A...
Eprotirome
go.drugbank.com/drugs/DB05035InvestigationalEprotirome which is a compound with promising properties for treatment of obesity and dyslipidemia. Eprotirome increases the body’s energy consumption and reduces body weight and markedly reduces blood lipids and blood glucose.